This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote
by Arpita Dutt
It's time to look at these 5 CAR-T stocks given the interest generated by a positive FDA advisory panel vote for Novartis' (NVS) experimental CAR-T treatment.
Novartis CAR-T Therapy Drug Recommended by FDA Panel
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has unanimously (10-0) recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel).
Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label
by Zacks Equity Research
Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.
Pfizer's (PFE) Leukemia Candidate Receives Approval in EU
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its leukemia candidate, Besponsa, has been approved by the European Commission.
How Kite Pharma Is Revolutionizing the Fight Against Cancer
by Eric Dutram
Immunotherapy is a hot corner of the biotech world. Learn how companies in this sector fight cancer in this podcast which features Dr. David Chang, the Chief Medical Officer of Kite Pharma. Do not miss it!
M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks
by Arpita Dutt
The biotech sector's fundamentals remain strong.
ETF Winner of 1H17 and its Top 5 Stocks
by Sweta Killa
Inside the top performing ETF of the first half of 2017.
Why Is Kite Pharma (KITE) Up 6.3% Since the Last Earnings Report?
by Zacks Equity Research
Kite Pharma (KITE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why is Kite Pharma (KITE) Stock Up Close to 100% this Year?
by Zacks Equity Research
Shares of Kite Pharma, Inc. (KITE) were up around 5.6% on Thursday.
Kite Pharma (KITE) Releases Data on Lead Drug for Leukemia
by Zacks Equity Research
Kite Pharma, Inc. (KITE) announced results from phase I trial, ZUMA-3, on lead candidateKTE-C19 (axicabtagene ciloleucel) in adults with high burden relapsed/refractory acute lymphoblastic leukemia (r/r ALL).
Kite Pharma Cancer Drug BLA Gets Priority Review Status
by Zacks Equity Research
Kite Pharma, Inc. (KITE) announced that its biologics license application (BLA) for its experimental CAR-T therapy, axicabtagene ciloleucel has been accepted for priority review by the FDA.
Kite Pharma (KITE) Posts Q1 Loss, Reveals CAR-T Patient Death
by Zacks Equity Research
Kite Pharma, Inc. (KITE) reported wider-than-expected loss in the first quarter of 2017.
Here's Why Kite Pharma (KITE) Stock Is Plummeting Today
by Ryan McQueeney
Shares of Kite Pharma (KITE) slipped more than 13% in morning trading Monday after it was revealed that a cancer patient died from brain swelling following treatment with the company's CAR-T therapy KTE-C19.
Kite Pharma (KITE) Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
KITE reported first-quarter 2017 loss of 1.74 cents per share, wider than our consensus estimate of a loss of $1.68 cents per share.
Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards?
by Zacks Equity Research
Kite Pharma, Inc. (KITE) is expected to report first-quarter 2017 results on May 8 before the market opens.
Novartis' (NVS) CTL109 BLA Gets Breakthrough Therapy Status
by Zacks Equity Research
Novartis (NVS) announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, CTL019.
Kite Pharma Completes Filing for CAR-T Therapy with FDA
by Zacks Equity Research
Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.
Novartis' CTL109 BLA Gets Priority Review Status from FDA
by Zacks Equity Research
Novartis A.G. (NVS) announced that the FDA has accepted and granted priority review designation to its biologics license application (BLA) for pipeline candidate, CTL019 (tisagenlecleucel-T).
Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval
by Zacks Equity Research
Pfizer, Inc. (PFE) and German partner Merck KGaA's investigational cancer treatment, avelumab, was approved by the FDA for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer.
Kite Pharma (KITE) Posts Q4 Loss; Up on Positive Cancer Data
by Zacks Equity Research
Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the fourth quarter of 2016.
Kite Pharma (KITE) Q4 Loss Narrower than Expected
by Zacks Equity Research
KITE reported fourth quarter 2016 loss of 1.70 cents per share, narrower than our consensus estimate of a loss of $1.75 cents per share.
Allergan (AGN) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Allergan plc (AGN) will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.
GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.
Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
by Arpita Dutt
The Q4 earnings season has started on a good note with both earnings and revenue growth improving compared to recent quarters.
Biogen (BIIB) Presents Positive Phase III Data on Spinraza
by Zacks Equity Research
Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).